Q-omics provides the consensus-scored MIR582 profile across patient tissues and cancer cell-line models. MIR582 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR582 is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, MIR582 RNA expression shows 7,601 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight KIRC, KIRP, and COAD as cancer lineages where MIR582 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR582 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR582 survival associations across molecular data types. MIR582 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR582 RNA expression–survival associations across cancer types. High MIR582 expression shows unfavorable associations in KIRC, THYM, STAD, LUAD, KICH and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR582 RNA expression.
This table summarizes MIR582 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR582. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR582 shows lower tumor expression in KIRP. The KIRP box plot shows higher MIR582 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .042).
This table shows molecular features associated with MIR582 in patient tissues and cancer cell lines. In patient samples, MIR582 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
